As previously communicated, Pharmacolog i Uppsala AB (“Pharmacolog” or “the Company”) has carried out a directed new issue of shares and warrants of series TO1 (“Warrants”) and distributed Warrants to the shareholders in the Company. The first day to trade the Warrants on the Nasdaq First North Growth Market is July 28, 2020.
Terms for warrants of series TO1
Each TO1 series warrant entitles the holder to subscribe for one (1) new Series B share in the Company for cash payment corresponding to 70 percent of the volume-weighted average price of the Company’s share on the Nasdaq First North Growth Market during the period from July 26, 2021 through August 6, 2021, however, the subscription price may amount to a maximum of SEK 12 and a minimum quota value for Pharmacolog’s shares. The subscription period for subscription of shares with the support of warrants of series TO1 will run from August 9, 2021 to August 20, 2021. With a maximum allotment and full exercise of warrants of the TO1 series, Pharmacolog can be provided with up to approximately SEK 33.8 million, depending on the subscription price.
Mangold Fondkommission AB was the financial advisor and the law firm Lindahl was the legal advisor in connection with the private placement and the distribution of Warrants to the shareholders.
Pharmacolog is specialized in developing systems and solutions for more effective and safer use of intravenous drugs. The company’s first product, DrugLog®, enables a nurse or pharmacist to quickly and easily verify that an injectable drug has the right identity and concentration. Pharmacolog’s long-term vision is an individually optimized medication for each individual patient, considering all available parameters in the control and distribution of the drug. Further information regarding the company is available at http://www.pharmacolog.com. The company’s Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through CA@mangold.se.